SCHEMBL23927097

CC(C)(C)OC(=O)N1C[C@H](N(OCc2ccccc2)S(=O)(=O)c2ccccc2[N+](=O)[O-])C[C@H]2CN(CCO[Si](C)(C)C(C)(C)C)C(=O)[C@H]21

nearest known ligand 0.35

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	MCL1	Q07820	9/20	0.35

▸	BCL2	P10415	4/20	0.35

▸	BCL2L1	Q07817	2/20	0.35

▸	MEN1	O00255	1/20	0.34

▸	KMT2A	Q03164	1/20	0.34

▸	JAK2	O60674	1/20	0.32

▸	JAK1	P23458	1/20	0.32

▸	ALDH1A1	P00352	2/20	0.32

▸	LMNA	P02545	2/20	0.32

▸	POLB	P06746	2/20	0.32

▸	KLK7	P49862	1/20	0.31

▸	MET	P08581	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19990663	0.94	KMT2A (0.34)	MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL22368503	0.86	MEN1 (0.36)	MCL1BCL2BCL2L1MEN1KMT2A
SCHEMBL23927101	0.86	MEN1 (0.36)	MCL1BCL2BCL2L1MEN1KMT2A
SCHEMBL19990908	0.83	KMT2A (0.35)	MEN1KMT2AJAK2JAK1ALDH1A1
SCHEMBL19990607	0.78	KMT2A (0.35)	MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL15347310	0.76	MEN1 (0.42)	MCL1BCL2MEN1KMT2AJAK2
SCHEMBL15347309	0.76	MEN1 (0.42)	MCL1BCL2MEN1KMT2AJAK2
SCHEMBL15347117	0.76	MEN1 (0.43)	MCL1BCL2BCL2L1MEN1KMT2A
SCHEMBL15347277	0.75	MEN1 (0.42)	MCL1BCL2BCL2L1MEN1KMT2A
SCHEMBL15347276	0.75	MEN1 (0.42)	MCL1BCL2BCL2L1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3698796-B1	PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS	NOVARTIS AG (CH)	2021-10-27	—	—	EP	disclosed